Skip to main content
Premium Trial:

Request an Annual Quote

Chondrogene Posts Slight Decline in Q1 Revenue Amid Surge in R&D Spending, Net Loss

NEW YORK, May 31 (GenomeWeb News) - Chondrogene's first-quarter revenue declined around 1 percent as R&D spending surged 85 percent and net losses 26.5 percent year over year, the company reported today.

 

Total receipts for the three months ended March 31 declined to CA$868,222 ($788,312) from CA$878,251 year over year.

 

Though the brunt of the total receipts were from a one-time payment from Pfizer that was unchanged from the first quarter 2005, the decline in the current period stemmed from lower fees and service payments, which fell to CA$196,459 in the current quarter from CA$206,488 year over year.

 

Chondrogene said R&D spending swelled to CA$ 2.4 million from CA$1.3 million in the year-ago period.

 

First-quarter net loss jumped to CA$2.2 million from CA$1.1 million year over year.

 

Chondrogene said it had around CA$4.4 million in cash and equivalents as of March 31.

 

Since the quarter ended, Chondrogene closed a CA$25 million private stock placement that will enable the company to "drive commercialization" of its lead product, the ColonSentry test for colon cancer.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.